Clinical data | |
---|---|
Trade names | Bromday, Xibrom, Prolensa, Yellox, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a611018 |
License data | |
Routes of administration | Eye drops |
Drug class | NSAID[1] |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 99.8% |
Metabolism | CYP2C9 |
Metabolites | Lactam, others |
Elimination half-life | 1.4 hours in aqueous humour |
Excretion | 82% urine, 13% faeces |
Identifiers | |
| |
Chemical and physical data | |
Formula | C15H12BrNO3 |
Molar mass | 334.169 g·mol−1 |
3D model (JSmol) | |
Melting point | 284 to 286 °C (543 to 547 °F) (bromfenac sodium·1.5H2O) |
| |
| |
(verify) |
Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) which is used for pain and inflammation after cataract surgery.[1] It is used as an eye drop twice per day for two weeks.[1]
Common side effects include red eyes, itchy eyes, and headache.[1] Other side effects may include slower wound healing, bleeding, and keratitis.[1] It works by blocking the production of prostaglandins.[1]
Bromfenac was approved for medical use in the United States in 2005.[1] It is available as a generic medication.[2] In the United States 1.7 ml of 0.09% solution costs about 51 USD as of 2021.[2] In the United Kingdom 5 ml of the solution costs the NHS 8.5 pounds.[3]
References edit
- ^ a b c d e f g h i "Bromfenac Monograph for Professionals". Drugs.com. Archived from the original on 21 January 2021. Retrieved 17 July 2021.
- ^ a b "Bromfenac Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 26 May 2020. Retrieved 17 July 2021.
- ^ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1241. ISBN 978-0-85711-369-6.
{{cite book}}
: CS1 maint: date format (link)